

10667182

=> d his

(FILE 'HOME' ENTERED AT 15:43:38 ON 25 JUN 2004)

FILE 'REGISTRY' ENTERED AT 15:43:52 ON 25 JUN 2004

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 56 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:44:38 ON 25 JUN 2004

L4 3 S L3

FILE 'BEILSTEIN' ENTERED AT 15:45:48 ON 25 JUN 2004

L5 0 S L1

L6 0 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 15:46:12 ON 25 JUN 2004

L7 0 S L3

L8 3 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:46:49 ON 25 JUN 2004


L9 3 S L8

L10 0 S L9 NOT L4

=> d l1

L1 HAS NO ANSWERS

L1 STR




10667182

=> d 1-3 bib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267332 CAPLUS
DN 140:303670
TI Preparation of imidazopyridines as 5-HT4 receptor agonists
IN Iguchi, Satoru; Katsu, Yasuhiro; Kon-I, Kana; Noguchi, Hirohide; Uchida, Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026869	A1	20040401	WO 2003-IB3971	20030908
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004122043	A1	20040624	US 2003-667188	20030917
PRAI	US 2002-412485P	P	20020920		
OS	MARPAT 140:303670				
GI					




AB The title compds. [I; R1 = H, halo; R2 = Me, Et; R3 = branched alkyl or alkyl substituted by alkoxy; with the proviso that when the terminal carbon atom of said alkyl group is substituted by said alkoxy group, said alkyl group is a branched alkyl group] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared E.g., a 6-step synthesis of I [R1 = Cl; R2 = Me; R3 = iso-Bu] which showed Ki of 0.82 nM against 5-HT4 binding, was given. This invention also provides a pharmaceutical composition comprising the compound I.


IT **519148-48-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)

RN 519148-48-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10667182




IT 519148-50-6P 519148-51-7P 519148-52-8P
519148-53-9P 676322-47-7P 676322-48-8P
676322-49-9P 676322-50-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)
RN 519148-50-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[[1-(2-
methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 519148-51-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-
dimethylbutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)

10667182



RN 519148-52-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519148-53-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667182




RN 676322-47-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2,2-dimethylpropyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 676322-48-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2,2-dimethylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



10667182


RN 676322-49-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-3-methylbutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676322-50-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-2,2-dimethylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 519147-99-0P 676322-53-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridinecarboxamides as 5-HT₄ receptor agonists)


RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10667182



RN 676322-53-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267331 CAPLUS
DN 140:303669
TI Preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as
5-HT4 receptor modulators
IN Katsu, Yasuhiro; Kon-I, Kana; Morita, Mikio; Noguchi, Hirohide; Uchida,
Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026868	A1	20040401	WO 2003-IB3945	20030908
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
					CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
					GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,


10667182

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-412426P P 20020920

OS MARPAT 140:303669

GI




AB The title compds. [I; R1 = H, halo; R2 = H, alkyl, aminocarbonyl, mono- or dialkylaminocarbonyl; R3 = alkyl which is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α = aryl, OH, oxo, heterocyclyl, etc.] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared E.g., a multi-step synthesis of I [R1 = Cl; R2 = H; R3 = 3,3-dimethyl-2-oxobutyl], starting from Et 6-[(2,2,-dimethylpropanoyl)amino]-2-fluoronicotinate, was given. All compds. I prepared in the working examples showed Ki of 0.19 nM to 47 nM with respect to the affinity to the 5-HT4 receptor. This invention also provides a pharmaceutical composition comprising the compound I.

IT 676351-57-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators)

RN 676351-57-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 676351-56-7P 676351-58-9P 676351-59-0P
676351-60-3P 676351-61-4P 676351-62-5P

10667182


676351-63-6P 676351-64-7P 676351-65-8P
676351-66-9P 676351-67-0P 676351-68-1P
676351-69-2P 676351-70-5P 676351-71-6P
676351-72-7P 676351-73-8P 676351-74-9P
676351-75-0P 676351-76-1P 676351-77-2P
676351-78-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as
5-HT₄ receptor modulators)


RN 676351-56-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethyl-
2-oxobutyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 676351-58-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[[1-(3,3-dimethyl-2-
oxobutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-59-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethyl-
2-oxobutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)

10667182



RN 676351-60-3 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(3-hydroxy-3-methyl-2-oxobutyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)



RN 676351-61-4 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)

10667182




RN 676351-62-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-oxo-2-(1-piperidinyl)ethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 676351-63-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)





RN 676351-64-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[3-(4-morpholinyl)-3-oxopropyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






RN 676351-65-8 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 676351-66-9 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10667182



RN 676351-67-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-3,3-dimethylbutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-68-1 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxybutyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


10667182



RN 676351-69-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxybutyl)-4-piperidinyl]methyl]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 676351-68-1
CMF C20 H30 Cl N5 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 676351-70-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10667182




RN 676351-71-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 676351-72-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-[(2R)-3-hydroxy-2-methylpropyl]-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10667182

RN 676351-73-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(1,3,3-trimethyl-2-oxobutyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)




RN 676351-74-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-[2-(1-methylcyclopropyl)-2-oxoethyl]-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 676351-75-0 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)



RN 676351-76-1 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-
[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidinyl]methyl]- (9CI)
(CA INDEX NAME)




10667182

PAGE 2-A


|
NH₂

RN 676351-77-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-1,1-dimethylethyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-78-3 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-[(tetrahydro-2H-pyran-4-yl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

|
NH₂


10667182

IT 519147-99-0P 676322-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as
5-HT4 receptor modulators)


RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-
a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



RN 676322-53-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-
a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:335105 CAPLUS

DN 138:353992

TI Preparation of imidazopyridines as 5-HT4 receptor modulators


IN Fenwick, David Roy; Gymer, Geoffrey Edward; Noguchi, Hirohide; Stobie,
Alan; Uchida, Chikara

PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.

10667182

SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035649	A1	20030501	WO 2002-IB4098	20021003
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092699	A1	20030515	US 2002-251109	20020920
	US 6624162	B2	20030923		
	US 2004034226	A1	20040219	US 2003-617920	20030710
PRAI	US 2001-343371P	P	20011022		
	US 2002-412485P	P	20020920		
	US 2002-251109	A3	20020920		
OS	MARPAT 138:353992				
GI					



AB Title compds. [I; R1 = H, halo, alkyl; R2, R3 = H, alkyl, alkenyl, alkynyl, aminoalkyl, hydroxyalkyl; R2R3N = (substituted) heterocyclyl; R4 = H, halo, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R5 = H, halo, alkyl, alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R6 = H, alkyl, alkoxyalkyl; X = NR9 wherein R9 = H or alkyl; and Y = (CR7R8)n; n = 0-5], were prepared for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, etc. (no data). Thus, Et 5-amino-6-chloroimidazo[1,2-a]pyridine-8-carboxylate (preparation given) was stirred 20 min. with carbonyldiimidazole; 1-(1-butyl-4-piperidinyl)methanamine and Et3N were added followed by stirring overnight to give 40% 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloroimidazo[1,2-a]pyridine-8-carboxamide.

IT **519147-74-1P 519147-75-2P 519147-78-5P 519147-80-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of imidazopyridines as 5-HT4 receptor modulators)


RN 519147-74-1 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro- (9CI) (CA INDEX NAME)


10667182



RN 519147-75-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 519147-78-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-methyl- (9CI) (CA INDEX NAME)



10667182

RN 519147-80-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxypropyl)-4-piperidiny]methyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 519148-29-9P 519148-30-2P 519148-31-3P
519148-32-4P 519148-33-5P 519148-34-6P
519148-36-8P 519148-37-9P 519148-40-4P
519148-41-5P 519148-42-6P 519148-43-7P
519148-45-9P 519148-46-0P 519148-48-2P
519148-50-6P 519148-51-7P 519148-52-8P
519148-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519148-29-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, N-[(1-butyl-4-piperidiny)methyl]-6-chloro-5-(methylamino)- (9CI) (CA INDEX NAME)




RN 519148-30-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 6-chloro-N-[[1-(3-methoxypropyl)-4-piperidiny]methyl]-5-(methylamino)- (9CI) (CA INDEX NAME)


10667182



RN 519148-31-3 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 519148-32-4 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-3-chloro-2-ethyl- (9CI) (CA INDEX NAME)



10667182


RN 519148-33-5 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 519148-34-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-ethyl-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 519148-36-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-propyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 519148-02-8


CMF C21 H32 Cl N5 O

10667182




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 519148-37-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 519148-40-4 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)


10667182



RN 519148-41-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 519148-42-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10667182


RN 519148-43-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 519148-45-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 519148-46-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-chloro- (9CI) (CA INDEX NAME)

10667182




RN 519148-48-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519148-50-6 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



10667182


RN 519148-51-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethylbutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 519148-52-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519148-53-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667182




IT 519147-97-8P 519147-98-9P 519147-99-0P
519148-02-8P 519148-09-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519147-97-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny)methyl]-6-chloro-2-ethyl- (9CI) (CA INDEX NAME)



RN 519147-98-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(3-methoxypropyl)-4-piperidiny)methyl]- (9CI) (CA INDEX NAME)

10667182




RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 519148-02-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-propyl- (9CI) (CA INDEX NAME)



10667182

RN 519148-09-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny)methyl]-6-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT